Selank (Russian: Cеланк) is a nootropic anxiolytic peptide based drug developed by the Institute of Molecular Genetics of the Russian Academy of Sciences. Selank is a heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro (TKPRPGP). It is a synthetic analogue of the human tuftsin. It was initially developed to modulate brain activity and the immune system and may help regulate neurotransmitters like serotonin and dopamine to promote cognitive stability and emotional balance.
{{Infobox drug | Verifiedfields = changed | Watchedfields = changed | verifiedrevid = 451548869 | IUPAC_name = 1-[2-({1-[2-({1-[6-Amino-2-(2-amino-3-hydroxy-butyrylamino)-hexanoyl]-pyrrolidine-2-carbonyl}-amino)-5-guanidino-pentanoyl]-pyrrolidine-2-carbonyl}-amino)-acetyl]-pyrrolidine-2-carboxylic acid | image = Selank.png | image_class = skin-invert-image
| tradename = | licence_EU = | pregnancy_category = | legal_status = Unscheduled | routes_of_administration = Nasal muscosa, IV
Discovered by embedding cosine similarity (sentence-transformers MiniLM, 384-dim).